top of page
Search

Check out updates to COVID-19 management guideline!

Our guideline working group has reviewed latest evidence and recommends therapeutic anticoagulation (instead of prophylactic) for mild and moderate COVID-19. This is based on review of latest evidence from 3 international trials, demonstrating marked benefit (net benefit in terms of organ-support free days, irrespective of D-dimer levels). No benefit (and possible harm) for severe COVID-19. Endorsed by MUHC P&T committee!

 
 
 

Recent Posts

See All
Linezolid TDM

INESSS approved the TDM of Linezolid in May 2024 It is now available in the MUHC (via HSJ labs) The ASP committee is happy to publish a...

 
 
 
MUHC ASP annual report 2022-2023

The ASP chairs are happy to publish the MUHC ASP annual report 2022-2023, now available in the Resources section of the MUHC ASP website....

 
 
 
S.aureus bacteremia

The ASP committee is happy to give you an early Christmas gift! We published the guidelines on management and treatment of Staphylococcus...

 
 
 

Comments

bottom of page